Kalaris Therapeutics (NASDAQ:KLRS) Raised to “Strong-Buy” at Wedbush

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by stock analysts at Wedbush to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research firms have also weighed in on KLRS. Wall Street Zen upgraded shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday. Morgan Stanley started coverage on shares of Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price objective for the company. Finally, Citizens Jmp reduced their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

Kalaris Therapeutics Trading Up 8.1%

Kalaris Therapeutics stock opened at $5.22 on Thursday. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $11.88. The firm has a market capitalization of $120.02 million, a price-to-earnings ratio of -2.43 and a beta of 0.15. The firm has a 50 day simple moving average of $6.58 and a 200 day simple moving average of $7.52.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06. On average, equities research analysts forecast that Kalaris Therapeutics will post -2.15 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KLRS. XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics during the 2nd quarter valued at $65,000. Fortis Capital Advisors LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at $231,000. Belpointe Asset Management LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at $231,000. Johnson Financial Group Inc. purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at $58,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at $130,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.